N-Terminal peptidic boronic acids selectively inhibit human ClpXP

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Enzymology

Background:

• Protease inhibitors are crucial for understanding enzyme function and disease.
• Current peptidic boronic acids target C-terminal sites, limiting inhibitor design.
• Human ClpXP is an ATP-dependent serine protease in the mitochondrial matrix with an unclear physiological role.

Purpose of the Study:

• To synthesize and develop novel N-terminal peptidic boronic acids as protease inhibitors.
• To explore a new strategy for protease inhibition targeting S' sites.
• To identify the first selective inhibitor of human ClpXP.

Main Methods:

• Synthesis of N-terminal peptidic boronic acids.
• Screening of synthesized compounds against target proteases.
• Characterization of inhibitor selectivity and potency.

Main Results:

• Successful synthesis of N-terminal peptidic boronic acids.
• Identification of the first selective inhibitor for human ClpXP.
• Demonstration that N-terminal peptidic boronic acids can interrogate S' sites for selectivity.

Conclusions:

• N-terminal peptidic boronic acids represent a new class of protease inhibitors.
• This strategy complements existing C-terminal boronic acids.
• The discovered ClpXP inhibitor will aid in elucidating its mitochondrial functions.